KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 5.12% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $4.2 billion, up 46.35%, while the annual FY2025 figure was $1.3 billion, 5.12% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.3 billion in Q4 2025 per EBS's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.2 billion in Q4 2022 and bottomed at $1.3 billion in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $2.3 billion, with a median of $2.8 billion recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 27.27% in 2021, then plummeted 42.42% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.0 billion in 2021, then increased by 7.05% to $3.2 billion in 2022, then tumbled by 42.42% to $1.8 billion in 2023, then fell by 23.78% to $1.4 billion in 2024, then decreased by 5.12% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.3 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.4 billion in Q2 2025.